Pharma, R&D

Scoop: Pfizer once again takes out the budget ax, lopping off 150 R&D staffers and 5 preclinical biosimilar drugs

Pfizer is taking the ax to its preclinical R&D group for biosimilars in a move designed to end — at least for now — any new expansion of the pipeline for knockoffs.

After messages began to pop up on social media from staffers getting the ax, a Pfizer spokesperson confirmed to me that the company is cutting 150 staffers at 2 sites, in Lake Forest, IL and Chennai, India and ending development of 5 preclinical programs.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->